Clinical efficacy and safety of amiodarone and benazepril in the treatment of paroxysmal atrial fibrillation

Abstract

Objective To study the clinical efficacy and safety of amiodarone combined with benazepril in the treatment of paroxysmal atrial fibrillation. Methods Ninety patients with paroxysmal atrial fibrillation were selected, according to the random number table method, they were divided into observation group and control group, 45 cases in each group. The observation group was treated with amiodarone and benazepril, while the control group was treated with amiodarone alone. The total effective rate, left ventricular end-diastolic diameter, left ventricular ejection fraction, left ventricular diameter shortening index, B-type natriuretic peptide and adverse reactions were compared between the two groups after treatment. Results After treatment, in the observation group, the total effective rate (95.56%) was higher than that in the control group(75.55%), the left ventricular systolic diameter and B-type natriuretic peptide[(30.25±1.32) mm, (112.45±3.89) ng/L] were lower than those in the control group [(36.78±2.14) mm, (132.25±4.54)ng/L], the left ventricular ejection fraction and left venntricular diameter shortening rate (32.21%±1.45%, 54.12%±2.32%) were higher than those in the control group (25.78%±1.59%, 46.75 %± 1.92%), the adverse reaction incidence rate (2.22%) was lower than that in the control group (13.33%), the differences were statistically significant (all P<0.05). Conclusions The combination of amiodarone and benazepril in the treatment of paroxysmal atrial fibrillation has a significant clinical effect and a low incidence of adverse reactions. It is a safe and feasible treatment method and worthy of clinical popularization. Key words: Amiodarone; Benazepril; Paroxysmal atrial fibrillation